Voyager Therapeutics shares surge 21.03% premarket on strategic collaborations, pipeline advancements, and $229M cash runway through 2028.

Voyager Therapeutics (VYGR) surged 21.03% in premarket trading following its third-quarter 2025 earnings report, which highlighted key advancements in its pipeline and financial resilience. The company announced initial preclinical data for its nonviral Voyager NeuroShuttle platform, demonstrating sustained brain delivery of therapeutics, and disclosed a $500 million milestone-laden collaboration with Transition Bio to develop TDP-43-targeting small molecules for ALS and FTD. Additionally, Voyager maintained a $229 million cash runway through 2028, underscoring its ability to fund R&D despite a widened net loss. The CEO emphasized strategic focus on multi-modality therapies and partnerships, aligning with investor optimism over long-term pipeline potential and technological differentiation in neurotherapeutics.